This is truly a binary event. An unqualified success in this study probably leads to a new SoC for colorectal-cancer screening; on the other hand, the stock’s $600M enterprise value has a long way to fall if the data are less than stellar.
IMO, no inference should be drawn one way or the other from the company’s decision to announce the results tomorrow morning rather than now.
Market Data 
Markets 
AI
